PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

NCT06639607 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Midline Glioma
Diffuse Midline High-grade Glioma
Medulloblastoma
Ependymoma

Interventions

BIOLOGICAL: PEP-CMV vaccine
BIOLOGICAL: Tetanus booster
BIOLOGICAL: Nivolumab
DRUG: Temozolomide

Sponsor

Washington University School of Medicine

Collaborators

[object Object]